4//SEC Filing
Coulie Bernard 4
Accession 0001209191-23-022362
CIK 0001746473other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 6:46 PM ET
Size
6.8 KB
Accession
0001209191-23-022362
Insider Transaction Report
Form 4
Coulie Bernard
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2023-03-30$26.52/sh−35,339$937,222→ 274,753 total
Holdings
- 409,317(indirect: See footnote)
Common Stock
Footnotes (2)
- [F1]Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.
- [F2]Shares are held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose.
Documents
Issuer
PLIANT THERAPEUTICS, INC.
CIK 0001746473
Entity typeother
Related Parties
1- filerCIK 0001808895
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 6:46 PM ET
- Size
- 6.8 KB